Bullish Options Sentiment in Allergan (AGN) Targets Upside Into 2018 -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Bullish Options Sentiment in Allergan (AGN) Targets Upside Into 2018 -Susquehanna
October 30, 2017 8:01 AM EDT
Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food and Drug Administration (CFDA) to market Ozurdex® (dexamethasone intravitreal implant 0.7 mg) for the treatment of adult patients with macular edema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).
Ozurdex is the first approved intravitreal injection for RVO in China. Retinal vein occlusion (RVO) is the second most common type of retinal vascular disorder after diabetic retinal disease and one of the most common causes of sudden, painless,... More
October 27, 2017 8:03 AM EDT
Allergan (NYSE: AGN) declared a quarterly dividend of $0.70 per share, or $2.8 annualized.
The dividend will be payable on December 15, 2017, to stockholders of record on November 17, 2017, with an ex-dividend date of November 16, 2017.
The annual yield on the dividend is 1.6 percent.
The... More
